Combination of anlotinib and albumin-bound paclitaxel in 2nd line and above treatment of advanced gastric cancer: A retrospective study

Table 1 Baseline clinical characteristics of the study cohort

Characteristics	No. of patients (%)
Age
Years	58
Range	47-71
Gender
Male	28 (77.78)
Female	8 (22.22)
Number of metastasis sites
2	25 (69.44)
3	11 (30.56)
Metastatic site
Lymph node	21 (58.33)
Peritoneum	14 (38.89)
Liver	12 (33.33)
Lung	9 (25.00)
Others	10 (27.78)
Primary tumor site
Gastric	31 (86.11)
GEJ	5 (13.89)
ECOG score
0-1	30 (83.33)
2	6 (16.67)
Tumor grade
Well, differentiated	2 (5.56)
Moderately diff erentiated	9 (25.00)
Poorly differentiated	20 (55.56)
Unknown or missing	5 (13.89)
Histological subtype (Lauren classification)
Intestinal	16 (44.44)
Diffuse	10 (27.78)
Mixed	2 (5.56)
Unknown or not available	8 (22.22)
Previous treatment
Triplet: Platinum and fl uoropyrimidine with anthracycline	8 (22.22)
Doublet: Platinum and fl uoropyrimidine	27 (75.00)
HER2, EGFR, or other	1 (2.78)
Treatment line
1	26 (72.22)
2	10 (27.78)

GEJ: Gastroesophageal Junction Adenocarcinoma; HER2: Human epidermal growth factor receptor 2; EGFR: Endothelial growth factor receptor; ECOG: Eastern Cooperative Oncology Group.

Table 2 Clinical efficacy of anlotinib combined with nab-ptx in second-line or above treatment for advanced gastric cancer

Clinical efficacy	Patient No.	Proportion (%)
Complete response	0	0
Partial response	16	44.44 (16/36)
Stable response	12	33.33 (12/36)
Progressive disease	8	22.23 (8/36)
Objective response		44.44
Median PFS		6.0 months
Disease control rate		77.78
Median OS	12.0 months

OS: Overall survival; PFS: Progression-free survival.

Table 3 Adverse reactions of anlotinib combined with nab-ptx in second-line or above treatment for advanced gastric cancer, n (%)

Adverse events	Any grade	Grade 3 or 4
Hematological
Leukopenia	13 (36.11)	2 (5.56)
Neutropenia	12 (33.33)	2 (5.56)
Thrombocytopenia	11 (30.56)	2 (5.56)
To anemia	10 (27.78)	0
Non-hematologic
Decreased appetite	19 (52.78)	0
Fatigue	16 (44.44)	0
Hypertension	11 (30.56)	2 (5.56)
Hand-foot syndrome	12 (33.33)	2 (5.56)
Proteinuria	9 (25.00)	2 (5.56)
Peripheral neuropathy	7 (19.44)	1 (2.78)
Elevated transaminase	7 (19.44)	1 (2.78)
Oral ulcer	6 (16.67)	0
Stomatitis	5 (13.89)	0
Abdominal pain	5 (13.89)	0
Diarrhea	5 (13.89)	0
Hyperbilirubinemia	3 (8.33)	0
Elevated LDH	3 (8.33)	0
ALP increased	3 (8.33)	0
Elevated GGT	3 (8.33)	0
Hypoproteinemia	4 (11.11)	0
Dysphagia	3 (8.33)	0
Dysphonia	3 (8.33)	0
Bleeding	0	0

LDH: Lactate dehydrogenase; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transferase.